| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinoblastoma | 15 | 2013 | 117 | 1.480 |
Why?
|
| Adenoviridae | 8 | 2020 | 610 | 1.160 |
Why?
|
| Genetic Vectors | 9 | 2020 | 970 | 1.090 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 13 | 1997 | 38 | 0.780 |
Why?
|
| Versicans | 2 | 2020 | 15 | 0.730 |
Why?
|
| Retinal Neoplasms | 7 | 2012 | 103 | 0.720 |
Why?
|
| Adenoviridae Infections | 1 | 2020 | 71 | 0.660 |
Why?
|
| Virus Replication | 2 | 2020 | 637 | 0.630 |
Why?
|
| Hyaluronan Receptors | 3 | 2020 | 68 | 0.620 |
Why?
|
| Photoreceptor Cells | 10 | 1996 | 94 | 0.520 |
Why?
|
| Proteolysis | 2 | 2020 | 193 | 0.520 |
Why?
|
| Antiviral Agents | 2 | 2020 | 824 | 0.490 |
Why?
|
| Genetic Therapy | 8 | 2020 | 733 | 0.470 |
Why?
|
| Retinal Rod Photoreceptor Cells | 6 | 1997 | 87 | 0.430 |
Why?
|
| Corneal Transplantation | 1 | 2012 | 45 | 0.400 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 716 | 0.400 |
Why?
|
| Transgenes | 2 | 2012 | 346 | 0.400 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 610 | 0.390 |
Why?
|
| Cyclic GMP | 6 | 1996 | 105 | 0.380 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 87 | 0.370 |
Why?
|
| DNA, Viral | 3 | 2020 | 500 | 0.310 |
Why?
|
| Hyaluronic Acid | 3 | 2020 | 109 | 0.310 |
Why?
|
| Dog Diseases | 5 | 1997 | 60 | 0.300 |
Why?
|
| Graft Rejection | 1 | 2012 | 628 | 0.300 |
Why?
|
| Gene Expression | 3 | 2012 | 1614 | 0.300 |
Why?
|
| Phosphoric Diester Hydrolases | 5 | 1993 | 70 | 0.280 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1850 | 0.270 |
Why?
|
| Oncolytic Viruses | 3 | 2013 | 77 | 0.250 |
Why?
|
| COS Cells | 2 | 2017 | 283 | 0.230 |
Why?
|
| Vitreous Body | 2 | 2020 | 101 | 0.230 |
Why?
|
| Retina | 8 | 2012 | 499 | 0.230 |
Why?
|
| Rod Cell Outer Segment | 7 | 1991 | 48 | 0.210 |
Why?
|
| Neoplasms | 1 | 2017 | 3024 | 0.190 |
Why?
|
| Animals | 33 | 2017 | 36377 | 0.190 |
Why?
|
| Picornaviridae | 2 | 2013 | 20 | 0.170 |
Why?
|
| Oncolytic Virotherapy | 2 | 2013 | 90 | 0.170 |
Why?
|
| Maleimides | 1 | 2020 | 11 | 0.170 |
Why?
|
| Administration, Ophthalmic | 1 | 2020 | 7 | 0.170 |
Why?
|
| Metalloproteases | 1 | 2020 | 15 | 0.170 |
Why?
|
| Diamines | 1 | 2020 | 8 | 0.170 |
Why?
|
| Hydroxamic Acids | 1 | 2020 | 65 | 0.170 |
Why?
|
| Dipeptides | 1 | 2020 | 62 | 0.170 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 173 | 0.170 |
Why?
|
| Permeability | 1 | 2020 | 131 | 0.170 |
Why?
|
| Amides | 1 | 2020 | 87 | 0.170 |
Why?
|
| rho-Associated Kinases | 1 | 2020 | 56 | 0.160 |
Why?
|
| Thiazoles | 1 | 2020 | 102 | 0.160 |
Why?
|
| Protein Kinase C | 1 | 2020 | 151 | 0.160 |
Why?
|
| Hydroxyurea | 1 | 2020 | 86 | 0.160 |
Why?
|
| HeLa Cells | 2 | 2020 | 828 | 0.160 |
Why?
|
| Indoles | 1 | 2020 | 201 | 0.160 |
Why?
|
| Cattle | 11 | 1997 | 587 | 0.160 |
Why?
|
| Pyridines | 1 | 2020 | 247 | 0.150 |
Why?
|
| Conjunctiva | 1 | 2020 | 194 | 0.150 |
Why?
|
| Viral Proteins | 1 | 2020 | 360 | 0.150 |
Why?
|
| Magnesium | 2 | 1995 | 127 | 0.150 |
Why?
|
| Dogs | 5 | 1997 | 798 | 0.140 |
Why?
|
| Eye Neoplasms | 2 | 2013 | 53 | 0.140 |
Why?
|
| Lead | 2 | 1995 | 24 | 0.140 |
Why?
|
| DNA, Recombinant | 1 | 2017 | 106 | 0.140 |
Why?
|
| STAT Transcription Factors | 1 | 2017 | 25 | 0.140 |
Why?
|
| Janus Kinases | 1 | 2017 | 33 | 0.140 |
Why?
|
| src-Family Kinases | 1 | 2017 | 97 | 0.130 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 148 | 0.130 |
Why?
|
| Antigens, CD | 2 | 2012 | 452 | 0.130 |
Why?
|
| Retinitis Pigmentosa | 2 | 1996 | 95 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2020 | 341 | 0.130 |
Why?
|
| Genes, Reporter | 1 | 2017 | 394 | 0.130 |
Why?
|
| Signal Transduction | 2 | 2020 | 4897 | 0.130 |
Why?
|
| Phenytoin | 1 | 1996 | 64 | 0.130 |
Why?
|
| Humans | 37 | 2020 | 133390 | 0.120 |
Why?
|
| Blotting, Western | 6 | 2010 | 1134 | 0.120 |
Why?
|
| Eye Proteins | 3 | 2012 | 233 | 0.120 |
Why?
|
| Neoplasm Transplantation | 4 | 2011 | 399 | 0.120 |
Why?
|
| Pineal Gland | 1 | 1995 | 22 | 0.120 |
Why?
|
| Thymidine Kinase | 3 | 2010 | 95 | 0.120 |
Why?
|
| Vision, Ocular | 2 | 1994 | 133 | 0.120 |
Why?
|
| Retinal Degeneration | 4 | 2001 | 104 | 0.120 |
Why?
|
| Disease Models, Animal | 6 | 2013 | 4778 | 0.120 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 1995 | 77 | 0.120 |
Why?
|
| Kinetics | 8 | 1995 | 1355 | 0.110 |
Why?
|
| Adenoviruses, Human | 2 | 2005 | 99 | 0.110 |
Why?
|
| Brain Neoplasms | 4 | 2013 | 1407 | 0.110 |
Why?
|
| Eye | 4 | 2010 | 245 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 801 | 0.110 |
Why?
|
| Cell Adhesion | 2 | 2013 | 362 | 0.110 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1996 | 244 | 0.110 |
Why?
|
| Anticonvulsants | 1 | 1996 | 392 | 0.100 |
Why?
|
| Ion Channels | 2 | 1992 | 207 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2017 | 832 | 0.100 |
Why?
|
| Mutation | 5 | 2013 | 6290 | 0.100 |
Why?
|
| Fanconi Anemia | 1 | 1993 | 45 | 0.100 |
Why?
|
| Ganciclovir | 2 | 2005 | 104 | 0.100 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2012 | 62 | 0.100 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2012 | 88 | 0.100 |
Why?
|
| Interleukin-12 | 1 | 2012 | 122 | 0.090 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 3751 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1993 | 242 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 5 | 1995 | 1068 | 0.090 |
Why?
|
| Phytohemagglutinins | 1 | 1990 | 13 | 0.090 |
Why?
|
| Retinal Diseases | 1 | 1993 | 180 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 781 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 5 | 2013 | 1102 | 0.080 |
Why?
|
| Antigen-Antibody Complex | 3 | 1985 | 67 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2012 | 379 | 0.080 |
Why?
|
| Lymphocytes | 2 | 1990 | 440 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 154 | 0.080 |
Why?
|
| Glioma | 2 | 2013 | 538 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 607 | 0.080 |
Why?
|
| Leukemia, Lymphoid | 4 | 1988 | 110 | 0.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1996 | 809 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 644 | 0.080 |
Why?
|
| Choroid | 2 | 2006 | 41 | 0.080 |
Why?
|
| Peptides | 1 | 2012 | 859 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 1417 | 0.070 |
Why?
|
| DNA Replication | 1 | 1990 | 361 | 0.070 |
Why?
|
| Monocytes | 1 | 1990 | 360 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 352 | 0.070 |
Why?
|
| Transduction, Genetic | 2 | 2006 | 296 | 0.070 |
Why?
|
| Vincristine | 1 | 1988 | 195 | 0.070 |
Why?
|
| Eye Enucleation | 2 | 2006 | 50 | 0.070 |
Why?
|
| Dextrans | 1 | 2007 | 47 | 0.070 |
Why?
|
| Ureteroscopy | 1 | 2007 | 20 | 0.070 |
Why?
|
| Microspheres | 1 | 2007 | 75 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 1995 | 364 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 1755 | 0.070 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2007 | 82 | 0.060 |
Why?
|
| Gene Transfer Techniques | 2 | 2005 | 365 | 0.060 |
Why?
|
| Neoplasm Seeding | 1 | 2005 | 13 | 0.060 |
Why?
|
| Medulloblastoma | 1 | 2010 | 570 | 0.060 |
Why?
|
| Mice | 14 | 2013 | 18910 | 0.060 |
Why?
|
| Optic Nerve | 1 | 2006 | 119 | 0.060 |
Why?
|
| Brain Diseases | 1 | 1988 | 310 | 0.060 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2007 | 216 | 0.060 |
Why?
|
| Child | 9 | 2020 | 25733 | 0.060 |
Why?
|
| Electroretinography | 2 | 1996 | 123 | 0.060 |
Why?
|
| Trypsin | 2 | 1996 | 95 | 0.050 |
Why?
|
| Receptors, Virus | 1 | 2004 | 110 | 0.050 |
Why?
|
| Egtazic Acid | 2 | 1995 | 24 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 1996 | 644 | 0.050 |
Why?
|
| Seizures | 1 | 1988 | 889 | 0.050 |
Why?
|
| Cell Line | 5 | 2006 | 2836 | 0.050 |
Why?
|
| RNA, Messenger | 4 | 2010 | 2899 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 432 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2013 | 252 | 0.050 |
Why?
|
| Molecular Weight | 3 | 1990 | 388 | 0.040 |
Why?
|
| Immunosorbent Techniques | 2 | 1995 | 26 | 0.040 |
Why?
|
| Rats | 4 | 2000 | 3883 | 0.040 |
Why?
|
| CD40 Ligand | 1 | 2001 | 65 | 0.040 |
Why?
|
| Cloning, Molecular | 3 | 1997 | 911 | 0.040 |
Why?
|
| Female | 11 | 2020 | 71455 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2001 | 158 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2013 | 613 | 0.040 |
Why?
|
| Calmodulin | 3 | 1990 | 224 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2001 | 158 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2001 | 250 | 0.040 |
Why?
|
| Calcium | 3 | 1995 | 1145 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2003 | 186 | 0.040 |
Why?
|
| Flow Cytometry | 3 | 2012 | 836 | 0.040 |
Why?
|
| T-Lymphocytes | 3 | 2010 | 1814 | 0.040 |
Why?
|
| DNA, Complementary | 2 | 1997 | 472 | 0.040 |
Why?
|
| Infant | 8 | 2007 | 13158 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2001 | 178 | 0.040 |
Why?
|
| Base Sequence | 5 | 1997 | 3170 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1999 | 66 | 0.040 |
Why?
|
| Public Policy | 1 | 1999 | 54 | 0.040 |
Why?
|
| Peer Review, Research | 1 | 1999 | 46 | 0.040 |
Why?
|
| B-Lymphocytes | 2 | 1979 | 550 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1999 | 140 | 0.040 |
Why?
|
| Molecular Sequence Data | 5 | 1997 | 3967 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2013 | 1006 | 0.040 |
Why?
|
| Cell Separation | 1 | 1979 | 234 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 1999 | 245 | 0.040 |
Why?
|
| Chromatography, Ion Exchange | 2 | 1990 | 67 | 0.040 |
Why?
|
| Amino Acid Sequence | 4 | 1997 | 2781 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 258 | 0.030 |
Why?
|
| Transducin | 1 | 1997 | 32 | 0.030 |
Why?
|
| Blood Platelets | 2 | 1982 | 340 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 3480 | 0.030 |
Why?
|
| Restriction Mapping | 2 | 1993 | 192 | 0.030 |
Why?
|
| Codon | 2 | 1993 | 108 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1979 | 435 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 2 | 2010 | 133 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 366 | 0.030 |
Why?
|
| Homozygote | 2 | 1997 | 560 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 667 | 0.030 |
Why?
|
| Nerve Degeneration | 1 | 1996 | 129 | 0.030 |
Why?
|
| Cyclic Nucleotide-Gated Cation Channels | 2 | 1992 | 16 | 0.030 |
Why?
|
| United States | 2 | 2001 | 11677 | 0.030 |
Why?
|
| Reference Values | 1 | 1996 | 739 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1991 | 312 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2013 | 2025 | 0.030 |
Why?
|
| Genes, Retinoblastoma | 1 | 2013 | 21 | 0.030 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 6 | 1 | 1993 | 13 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2013 | 28 | 0.030 |
Why?
|
| Macromolecular Substances | 1 | 1993 | 183 | 0.030 |
Why?
|
| Isoenzymes | 2 | 1984 | 231 | 0.020 |
Why?
|
| Thalassemia | 1 | 1992 | 11 | 0.020 |
Why?
|
| Globins | 1 | 1992 | 36 | 0.020 |
Why?
|
| PAX6 Transcription Factor | 1 | 2012 | 39 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2012 | 37 | 0.020 |
Why?
|
| Male | 10 | 2020 | 65685 | 0.020 |
Why?
|
| Immune Sera | 2 | 1985 | 95 | 0.020 |
Why?
|
| Luminescent Proteins | 2 | 2004 | 166 | 0.020 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 76 | 0.020 |
Why?
|
| Transplantation, Heterologous | 2 | 2011 | 275 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2013 | 1596 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 1310 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1992 | 59 | 0.020 |
Why?
|
| Infant, Newborn | 4 | 2006 | 8586 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 4 | 2006 | 4822 | 0.020 |
Why?
|
| Epitopes | 3 | 1984 | 446 | 0.020 |
Why?
|
| Diltiazem | 1 | 1991 | 14 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1991 | 71 | 0.020 |
Why?
|
| Lizards | 1 | 1991 | 10 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 2 | 2004 | 401 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2012 | 342 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1984 | 433 | 0.020 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 1992 | 56 | 0.020 |
Why?
|
| Adolescent | 4 | 2020 | 20505 | 0.020 |
Why?
|
| Heterozygote | 1 | 1993 | 718 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 1 | 1 | 1990 | 2 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 1990 | 104 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2001 | 3168 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 1992 | 202 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1992 | 128 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 1990 | 188 | 0.020 |
Why?
|
| Exons | 1 | 1992 | 832 | 0.020 |
Why?
|
| Sarcoma | 1 | 1992 | 209 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 1992 | 1123 | 0.020 |
Why?
|
| Immunoglobulins | 2 | 1980 | 174 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 2 | 1979 | 33 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 584 | 0.020 |
Why?
|
| Protein Conformation | 2 | 1997 | 870 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 991 | 0.020 |
Why?
|
| Phenotype | 3 | 1992 | 4551 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2007 | 90 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2007 | 14788 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1326 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 791 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 1988 | 122 | 0.020 |
Why?
|
| DNA | 1 | 1993 | 1674 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2012 | 869 | 0.020 |
Why?
|
| Prednisone | 1 | 1988 | 287 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 2804 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 1760 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 2526 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 168 | 0.020 |
Why?
|
| Necrosis | 1 | 2006 | 221 | 0.020 |
Why?
|
| Macrophages | 1 | 2010 | 703 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 364 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 401 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 2210 | 0.010 |
Why?
|
| Myocardium | 1 | 1990 | 1045 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 745 | 0.010 |
Why?
|
| Integrin alphaV | 1 | 2004 | 3 | 0.010 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2004 | 12 | 0.010 |
Why?
|
| Membrane Cofactor Protein | 1 | 2004 | 10 | 0.010 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 1984 | 19 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 1928 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1984 | 195 | 0.010 |
Why?
|
| Pregnancy | 1 | 1996 | 7524 | 0.010 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 1982 | 23 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 814 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 2161 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 1306 | 0.010 |
Why?
|
| Species Specificity | 2 | 1997 | 569 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2001 | 34 | 0.010 |
Why?
|
| Ear | 1 | 2001 | 27 | 0.010 |
Why?
|
| Hydrolysis | 2 | 1995 | 164 | 0.010 |
Why?
|
| Lac Operon | 1 | 2001 | 96 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2001 | 132 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1984 | 824 | 0.010 |
Why?
|
| Injections | 1 | 2001 | 156 | 0.010 |
Why?
|
| Haplorhini | 1 | 2000 | 121 | 0.010 |
Why?
|
| Integrins | 1 | 2001 | 103 | 0.010 |
Why?
|
| Brain | 2 | 1990 | 3223 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1988 | 1349 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1988 | 2171 | 0.010 |
Why?
|
| Mice, Inbred C3H | 2 | 1992 | 122 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1979 | 45 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1979 | 70 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 866 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1979 | 140 | 0.010 |
Why?
|
| Transfection | 1 | 2001 | 1089 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1979 | 98 | 0.010 |
Why?
|
| Lung | 2 | 1984 | 1557 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1979 | 61 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2005 | 1313 | 0.010 |
Why?
|
| Prodrugs | 1 | 1999 | 63 | 0.010 |
Why?
|
| Antigens | 1 | 1979 | 157 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2001 | 538 | 0.010 |
Why?
|
| Herpes Simplex | 1 | 1999 | 57 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2001 | 1079 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1979 | 145 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2001 | 445 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2001 | 522 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2001 | 506 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1979 | 302 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1979 | 253 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1979 | 440 | 0.010 |
Why?
|
| Prognosis | 1 | 2006 | 5074 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1979 | 724 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1997 | 673 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 1979 | 626 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 1979 | 675 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2001 | 746 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1995 | 261 | 0.010 |
Why?
|
| Adult | 3 | 2007 | 31786 | 0.010 |
Why?
|
| Inflammation | 1 | 2001 | 1590 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2007 | 17378 | 0.010 |
Why?
|
| Muridae | 1 | 1992 | 16 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1992 | 79 | 0.010 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 1992 | 13 | 0.010 |
Why?
|
| Poly A | 1 | 1992 | 60 | 0.010 |
Why?
|
| Centromere | 1 | 1992 | 75 | 0.010 |
Why?
|
| Risk Factors | 1 | 2006 | 11085 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 295 | 0.010 |
Why?
|
| Blood Component Transfusion | 1 | 1992 | 57 | 0.010 |
Why?
|
| Hyperbilirubinemia | 1 | 1992 | 42 | 0.010 |
Why?
|
| Platelet Count | 1 | 1992 | 144 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2007 | 12971 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1992 | 220 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1995 | 1733 | 0.010 |
Why?
|
| Gene Library | 1 | 1992 | 225 | 0.010 |
Why?
|
| Plasma | 1 | 1992 | 104 | 0.010 |
Why?
|
| Remission Induction | 1 | 1992 | 307 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1997 | 1833 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1991 | 143 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 1999 | 3981 | 0.010 |
Why?
|
| Time Factors | 1 | 2001 | 6569 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1992 | 321 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1992 | 664 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 1626 | 0.000 |
Why?
|
| Recurrence | 1 | 1992 | 1464 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1992 | 1252 | 0.000 |
Why?
|
| Anura | 1 | 1985 | 23 | 0.000 |
Why?
|
| Texas | 1 | 1992 | 3688 | 0.000 |
Why?
|
| Chemistry, Physical | 1 | 1982 | 31 | 0.000 |
Why?
|
| Chemical Phenomena | 1 | 1982 | 88 | 0.000 |
Why?
|
| Substrate Specificity | 1 | 1982 | 311 | 0.000 |
Why?
|
| Histones | 1 | 1985 | 568 | 0.000 |
Why?
|
| Peptide Hydrolases | 1 | 1982 | 149 | 0.000 |
Why?
|
| Terminology as Topic | 1 | 1982 | 233 | 0.000 |
Why?
|
| Karyotyping | 1 | 1980 | 324 | 0.000 |
Why?
|
| Absorption | 1 | 1979 | 53 | 0.000 |
Why?
|
| Potassium Chloride | 1 | 1979 | 55 | 0.000 |
Why?
|
| Solubility | 1 | 1979 | 144 | 0.000 |
Why?
|
| Antibody Specificity | 1 | 1979 | 206 | 0.000 |
Why?
|
| Rabbits | 1 | 1979 | 730 | 0.000 |
Why?
|
| Insulin | 1 | 1982 | 1244 | 0.000 |
Why?
|
| Aged | 1 | 1992 | 21605 | 0.000 |
Why?
|